AS1411

A Phase I open label study of AS1411 in advanced solid tumours. Objectives include determining the MTD and DLT of AS1411, to determine the PK profile of AS1411 and to obtain preliminary evidence of clinical and biological responses to AS1411 therapy.

Study of AS1411 in Advanced Solid Tumours

Phase I Open Label Study of AS1411 in Advanced Solid Tumours

Antisoma Research

Chris Smyth, VP Clinical Operations

Neoplasms

Blood and Lymph Conditions

All Conditions

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Neoplasms by Histologic Type

Hematologic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Cytarabine

Antimetabolites

Antiviral Agents

Immunosuppressive Agents

Immunologic Factors

AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7

AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7

Rob Stuart, MD

This is an open label randomized controlled phase II study of AS1411 combined with Cytarabine in the treatment of patients with primary refractory or relapsed acute myeloid leukemia.

A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Fredrik Erlandsson, MD

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Carcinoma

Carcinoma, Renal Cell

Kidney Neoplasms

Neoplasms, Glandular and Epithelial

Adenocarcinoma

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles

Greg Smith, MD

Harry Drabkin, MD

The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma

A Phase II Study of AS1411 in Renal Cell Carcinoma

A Phase II, Open Label, Single Arm Study of AS1411 in Patients With Metastatic Renal Cell Carcinoma

Chris Smyth

Symptoms and General Pathology

Acute Disease

AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.

The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of doses, when combined with cytarabine, in the treatment of patients with primary refractory or relapsed acute myeloid leukemia (AML).

Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

An Open Label Randomized Controlled Dose Escalating Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of AS1411 in Advanced Solid Tumours	NCT00881244	Advanced Solid ...	AS1411	18 Years -	Antisoma Research
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia	NCT01034410	Acute Myeloid L...	AS1411 Cytarabine	18 Years - 70 Years	Antisoma Research
Study of AS1411 in Advanced Solid Tumours	NCT00881244	Advanced Solid ...	AS1411	18 Years -	Antisoma Research
A Phase II Study of AS1411 in Renal Cell Carcinoma	NCT00740441	Metastatic Rena...	AS1411	18 Years -	Antisoma Research
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia	NCT00512083	Leukemia, Myelo...	AS1411	18 Years -	Antisoma Research

Spots Global Cancer Trial Database for as1411

Every month we try and update this database with for as1411 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for as1411

Every month we try and update this database with for as1411 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for as1411 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.